Diana Zabolotna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diana Zabolotna has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry I. Zabolotnyi
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
9 shared publications Ukraine Kyiv
9 shared publications- Tetyana V. Smagina
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
8 shared publications - Oleg F. Melnikov
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
7 shared publications - Yaroslav Kizim
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine
7 shared publications - Inna V. Gogunska
STATE INSTITUTION “INSTITUTE OF OTOLARYNGOLOGY NAMED AFTER PROF. O.S. KOLOMIYCHENKO OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE”, KYIV, UKRAINE
6 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 160 (1)
The use of Anti-Reflux therapy in patients with chronic rhinosinusitis associated with Laryngopharyngeal Reflux
Chronic rhinosinusitis is a persistent inflammatory condition of the nasal cavity and paranasal sinuses that lasts for at least three months and affects millions of individuals worldwide, representing a significant clinical and socioeconomic challenge due to its prolonged course, high symptom burden, and substantial recurrence rates even after optimized medical and surgical therapy. Although the disorder is widely recognized as multifactorial, with contributing elements such as impaired epithelial barrier function, altered microbiota composition, genetic susceptibility, environmental exposure, and dysregulated local and systemic immune responses, increasing attention has been directed toward the potential impact of laryngopharyngeal reflux as an overlooked but clinically important factor capable of sustaining inflammation in the upper aerodigestive tract. Experimental and clinical studies have demonstrated that refluxate containing pepsin and other gastric components may reach the nasopharynx and sinonasal mucosa, where it induces epithelial injury, promotes mucous hypersecretion, alters local microbial ecology, and triggers neurogenic inflammatory pathways, ultimately impairing mucociliary transport and facilitating bacterial colonization and secondary infection. Given that unsatisfactory postoperative outcomes remain a considerable problem and that reflux-related mucosal irritation has been implicated in delayed healing and disease persistence, the present study aimed to investigate whether postoperative antireflux treatment may influence symptom dynamics and recurrence rates in patients with chronic rhinosinusitis with or without nasal polyps who also exhibit signs of laryngopharyngeal reflux. A prospective clinical study included 52 patients examined at the Kolomiychenko Institute of Otolaryngology between 2023 and 2024. Patients were divided into two groups: 26 received proton pump inhibitor therapy with antacids in the postoperative period, while 26 did not. All underwent videoendoscopic rhinoscopy, laryngoscopy, and computed tomography of the paranasal sinuses. Symptoms were assessed by the Sino-Nasal Outcome Test-22, endoscopic manifestations by the Lund-Kennedy scoring system, and reflux status by the Reflux Symptom Index and Reflux Finding Score. Preoperatively, groups showed no significant differences. Three months after surgery, patients who received anti-reflux therapy had a significantly lower mean Sino-Nasal Outcome Test-22 score compared with controls, indicating greater symptom reduction, although endoscopic improvements were similar in both groups. During follow-up, recurrence was observed in 19.2% of treated patients and 30.8% of untreated patients, with a trend toward fewer recurrences under therapy, but without statistical significance due to limited sample size and short observation. The results confirm that signs of laryngopharyngeal reflux are common in patients with chronic rhinosinusitis and suggest that anti-reflux therapy may enhance symptom control and possibly reduce recurrence risk after surgery. Larger, long-term studies are needed to clarify the role of reflux management in comprehensive treatment strategies.
- 31 March 2026
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 160 (1)
Open AccessThe use of Anti-Reflux therapy in patients with chronic rhinosinusitis associated with Laryngopharyngeal Reflux
Chronic rhinosinusitis is a persistent inflammatory condition of the nasal cavity and paranasal sinuses that lasts for at least three months and affects millions of individuals worldwide, representing a significant clinical and socioeconomic challenge due to its prolonged course, high symptom burden, and substantial recurrence rates even after optimized medical and surgical therapy. Although the disorder is widely recognized as multifactorial, with contributing elements such as impaired epithelial barrier function, altered microbiota composition, genetic susceptibility, environmental exposure, and dysregulated local and systemic immune responses, increasing attention has been directed toward the potential impact of laryngopharyngeal reflux as an overlooked but clinically important factor capable of sustaining inflammation in the upper aerodigestive tract. Experimental and clinical studies have demonstrated that refluxate containing pepsin and other gastric components may reach the nasopharynx and sinonasal mucosa, where it induces epithelial injury, promotes mucous hypersecretion, alters local microbial ecology, and triggers neurogenic inflammatory pathways, ultimately impairing mucociliary transport and facilitating bacterial colonization and secondary infection. Given that unsatisfactory postoperative outcomes remain a considerable problem and that reflux-related mucosal irritation has been implicated in delayed healing and disease persistence, the present study aimed to investigate whether postoperative antireflux treatment may influence symptom dynamics and recurrence rates in patients with chronic rhinosinusitis with or without nasal polyps who also exhibit signs of laryngopharyngeal reflux. A prospective clinical study included 52 patients examined at the Kolomiychenko Institute of Otolaryngology between 2023 and 2024. Patients were divided into two groups: 26 received proton pump inhibitor therapy with antacids in the postoperative period, while 26 did not. All underwent videoendoscopic rhinoscopy, laryngoscopy, and computed tomography of the paranasal sinuses. Symptoms were assessed by the Sino-Nasal Outcome Test-22, endoscopic manifestations by the Lund-Kennedy scoring system, and reflux status by the Reflux Symptom Index and Reflux Finding Score. Preoperatively, groups showed no significant differences. Three months after surgery, patients who received anti-reflux therapy had a significantly lower mean Sino-Nasal Outcome Test-22 score compared with controls, indicating greater symptom reduction, although endoscopic improvements were similar in both groups. During follow-up, recurrence was observed in 19.2% of treated patients and 30.8% of untreated patients, with a trend toward fewer recurrences under therapy, but without statistical significance due to limited sample size and short observation. The results confirm that signs of laryngopharyngeal reflux are common in patients with chronic rhinosinusitis and suggest that anti-reflux therapy may enhance symptom control and possibly reduce recurrence risk after surgery. Larger, long-term studies are needed to clarify the role of reflux management in comprehensive treatment strategies.
- Open Access
- 1 January 2026
- Published by Vistka LTD
- Vol. 9 (1-2) , 25-31
EFFECTIVENESS OF ETHMOID NASALIZATION IN PATIENTS WITH POLYPOUS RHINOSINUSIS
Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a challenging clinical condition characterized by a high recurrence rate after conventional surgical treatment. Increasing attention has recently been paid to ethmoidal nasalization, a more radical surgical approach targeting inflamed mucosa as a potential source of type‑2 inflammation. Objective: To evaluate the effectiveness of modified ethmoid nasalization compared to classical functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 inflammation. Materials and methods: Twenty patients with CRSwNP, bronchial asthma, and eosinophilic inflammation (100% type 2) were enrolled. Patients were divided into two groups (n=10 each): group 1 – classical FESS with maximal mucosal preservation; group 2 – modified ethmoid nasalization with complete removal of ethmoid mucosa followed by free mucosal flap coverage from the nasal floor. Quality of life was assessed using the SNOT-22 questionnaire and reverse visual analog scale (VAS, 0-10, higher scores indicate better condition) preoperatively and at 3, 6, and 12 months postoperatively. Statistical analysis was performed using the independent samples t-test. Results: Groups were comparable at baseline (Lund-Mackay score: 22 vs 20; SNOT-22: 60.2 vs 62.6). At 12 months, mean reverse VAS score was 2.1 (95% CI 0.67-3.53) in the FESS group versus 7.1 (95% CI 5.67-8.53) in the nasalization group (p<0.001). SNOT-22 scores at 12 months were 21.4 (95% CI 8.52-34.28) versus 11.1 (95% CI -1.78-23.98), respectively (p=0.217). The most pronounced difference was observed at late follow-up time points, indicating more sustained improvement after nasalization. Conclusions: Modified ethmoid nasalization provides significantly better long-term subjective outcomes in quality of life compared to classical FESS in patients with eosinophilic CRSwNP. The technique appears promising for reducing recurrence rates and the need for systemic corticosteroids and biologic therapy. Keywords: chronic rhinosinusitis with nasal polyps, ethmoid nasalization, functional endoscopic sinus surgery, SNOT-22, visual analog scale, type 2 inflammation.
- 1 January 2026
- Published by Vistka LTD
- Vol. 9 (1-2) , 25-31
Open AccessEFFECTIVENESS OF ETHMOID NASALIZATION IN PATIENTS WITH POLYPOUS RHINOSINUSIS
Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a challenging clinical condition characterized by a high recurrence rate after conventional surgical treatment. Increasing attention has recently been paid to ethmoidal nasalization, a more radical surgical approach targeting inflamed mucosa as a potential source of type‑2 inflammation. Objective: To evaluate the effectiveness of modified ethmoid nasalization compared to classical functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 inflammation. Materials and methods: Twenty patients with CRSwNP, bronchial asthma, and eosinophilic inflammation (100% type 2) were enrolled. Patients were divided into two groups (n=10 each): group 1 – classical FESS with maximal mucosal preservation; group 2 – modified ethmoid nasalization with complete removal of ethmoid mucosa followed by free mucosal flap coverage from the nasal floor. Quality of life was assessed using the SNOT-22 questionnaire and reverse visual analog scale (VAS, 0-10, higher scores indicate better condition) preoperatively and at 3, 6, and 12 months postoperatively. Statistical analysis was performed using the independent samples t-test. Results: Groups were comparable at baseline (Lund-Mackay score: 22 vs 20; SNOT-22: 60.2 vs 62.6). At 12 months, mean reverse VAS score was 2.1 (95% CI 0.67-3.53) in the FESS group versus 7.1 (95% CI 5.67-8.53) in the nasalization group (p<0.001). SNOT-22 scores at 12 months were 21.4 (95% CI 8.52-34.28) versus 11.1 (95% CI -1.78-23.98), respectively (p=0.217). The most pronounced difference was observed at late follow-up time points, indicating more sustained improvement after nasalization. Conclusions: Modified ethmoid nasalization provides significantly better long-term subjective outcomes in quality of life compared to classical FESS in patients with eosinophilic CRSwNP. The technique appears promising for reducing recurrence rates and the need for systemic corticosteroids and biologic therapy. Keywords: chronic rhinosinusitis with nasal polyps, ethmoid nasalization, functional endoscopic sinus surgery, SNOT-22, visual analog scale, type 2 inflammation.
- Open Access
- 31 December 2025
- Published by Ukrainian Military Medical Academy in Ukrainian Journal of Military Medicine
- Vol. 6 (4) , 116-120
Особливості клінічного перебігу грибкового алергічного риносинуситу у військовослужбовців
Вступ. Алергічний грибковий риносинусит (АГРС) – підтип хронічного риносинуситу з поліпами, який характеризується наявністю носових поліпів, продукцією густого еозинофільного муцину та експансивними змінами уражених приносових пазух. Патогенез пов’язаний із імуноглобулін Е-опосередкованою гіперчутливістю І типу до грибкових антигенів. Основним методом лікування АГРС є хірургічне втручання. Мета. Визначити особливості перебігу алергічного грибкового риносинуситу у військовослужбовців порівняно з цивільними пацієнтами. Матеріали і методи. У період з червня 2022 по червень 2025 року на базі відділення запальних захворювань ЛОР-органів ДУ «Інститут отоларингології ім. проф. О.С. Коломійченка НАМН України» було обстежено та проліковано 43 пацієнти з ознаками АГРС. Середній вік обстежених становив 48,9 року. Чоловіки складали 67,4% (n=29), жінки – 32,6% (n=14). До І групи увійшли 31 цивільний пацієнт, до ІІ групи – 12 військовослужбовців. Результати. У пацієнтів ІІ групи переважало двобічне ураження приносових пазух (83,3%), тоді як серед пацієнтів І групи частіше відзначався однобічний процес (58,1%). Головний біль постійного характеру спостерігався у 64,5% хворих І групи та у 100% пацієнтів ІІ групи. У 80,6% пацієнтів І групи скарги тривали понад 3 роки, тоді як усі пацієнти ІІ групи (100%) зазначали тривалість симптомів менше 3 років. Погіршення назальних симптомів після перенесеного COVID-19 вказали 32,3% пацієнтів І групи, тоді як жоден пацієнт ІІ групи не відзначав подібного впливу інфекції. Висновки. Перебіг захворювання у військовослужбовців (ІІ група) характеризувався більш швидким розвитком і агресивним клінічним перебігом порівняно з цивільними пацієнтами (І група). У військовослужбовців алергічний грибковий риносинусит частіше спостерігався з обох сторін (83,3%), порівняно з цивільними (41,9%). Головний біль спостерігався у всіх військовослужбовців з АГРС, на відміну від цивільних пацієнтів, де головний біль був присутній у 64,5% хворих. Розвиток захворювання згідно даних анамнезу у пацієнтів ІІ групи перебігав швидше і агресивніше. На відміну від цивільних пацієнтів, у військовослужбовців впливу COVID-19 на виникнення чи перебіг захворювання не спостерігалося. Згідно даних нашого дослідження рецидиви спостерігалися в усіх групах і достовірної різниці між ними не було виявлено.
- 31 December 2025
- Published by Ukrainian Military Medical Academy in Ukrainian Journal of Military Medicine
- Vol. 6 (4) , 116-120
Open AccessОсобливості клінічного перебігу грибкового алергічного риносинуситу у військовослужбовців
Вступ. Алергічний грибковий риносинусит (АГРС) – підтип хронічного риносинуситу з поліпами, який характеризується наявністю носових поліпів, продукцією густого еозинофільного муцину та експансивними змінами уражених приносових пазух. Патогенез пов’язаний із імуноглобулін Е-опосередкованою гіперчутливістю І типу до грибкових антигенів. Основним методом лікування АГРС є хірургічне втручання. Мета. Визначити особливості перебігу алергічного грибкового риносинуситу у військовослужбовців порівняно з цивільними пацієнтами. Матеріали і методи. У період з червня 2022 по червень 2025 року на базі відділення запальних захворювань ЛОР-органів ДУ «Інститут отоларингології ім. проф. О.С. Коломійченка НАМН України» було обстежено та проліковано 43 пацієнти з ознаками АГРС. Середній вік обстежених становив 48,9 року. Чоловіки складали 67,4% (n=29), жінки – 32,6% (n=14). До І групи увійшли 31 цивільний пацієнт, до ІІ групи – 12 військовослужбовців. Результати. У пацієнтів ІІ групи переважало двобічне ураження приносових пазух (83,3%), тоді як серед пацієнтів І групи частіше відзначався однобічний процес (58,1%). Головний біль постійного характеру спостерігався у 64,5% хворих І групи та у 100% пацієнтів ІІ групи. У 80,6% пацієнтів І групи скарги тривали понад 3 роки, тоді як усі пацієнти ІІ групи (100%) зазначали тривалість симптомів менше 3 років. Погіршення назальних симптомів після перенесеного COVID-19 вказали 32,3% пацієнтів І групи, тоді як жоден пацієнт ІІ групи не відзначав подібного впливу інфекції. Висновки. Перебіг захворювання у військовослужбовців (ІІ група) характеризувався більш швидким розвитком і агресивним клінічним перебігом порівняно з цивільними пацієнтами (І група). У військовослужбовців алергічний грибковий риносинусит частіше спостерігався з обох сторін (83,3%), порівняно з цивільними (41,9%). Головний біль спостерігався у всіх військовослужбовців з АГРС, на відміну від цивільних пацієнтів, де головний біль був присутній у 64,5% хворих. Розвиток захворювання згідно даних анамнезу у пацієнтів ІІ групи перебігав швидше і агресивніше. На відміну від цивільних пацієнтів, у військовослужбовців впливу COVID-19 на виникнення чи перебіг захворювання не спостерігалося. Згідно даних нашого дослідження рецидиви спостерігалися в усіх групах і достовірної різниці між ними не було виявлено.
- Open Access
- 26 December 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 4,p. 120-126
Modern Aspects of Pathophysiology, Diagnosis and Treatment of Allergic Fungal Rhinosinusitis (Literature review)
Allergic fungal rhinosinusitis (AFRS) is classified as a primary, localized, with Th2-inflammatory response rhinosinusitis. It is characterized by the presence of nasal polyps, production of typical thick eosinophilic mucin, and expansive changes in the affected paranasal sinuses. The diagnosis is based on the diagnostic criteria which were established by John P. Bent, and Frederich A. Kuhn, which are met by 5 to 10% of all cases of chronic rhinosinusites. AFRS is more common in men and presents at a mean age range of 21–33 years. AFRS is a non-invasive form of fungal rhinosinusitis and usually affects individuals with atopy and type I hypersensitivity to fungi. Up to 24% of patients also have bronchial asthma. The mucin has a thick, sticky consistency, which is often described as “peanut butter-like”. Affected sinuses frequently undergo expansive changes that lead to erosion of bony structures. Patients with AFRS are unable to effectively clear fungal spores from the environment. This leads to the epithelial barrier dysfunction and the release of cytokines such as Interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin. This triggers a type 2 immune response and initiates an inflammatory cascade that leads to eosinophilia, nasal polyposis, and the formation of eosinophilic mucin. Surgical intervention is the primary and most essential step in the treatment of AFRS. The goals of surgery include removal of eosinophilic mucin, which contains fungi that provoke and sustain sinus inflammation, excision of nasal polyps, and wide opening of the sinus cavities to facilitate postoperative sinus irrigation and local therapy. Biological medications represent a promising direction for the treatment of chronic rhinosinusitis, especially in patients with comorbid patology such as asthma. The high risk of recurrence highlights the need for further research into new treatment methods and the development of standardized care protocols for future patient management.
- 26 December 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 4,p. 120-126
Open AccessModern Aspects of Pathophysiology, Diagnosis and Treatment of Allergic Fungal Rhinosinusitis (Literature review)
Allergic fungal rhinosinusitis (AFRS) is classified as a primary, localized, with Th2-inflammatory response rhinosinusitis. It is characterized by the presence of nasal polyps, production of typical thick eosinophilic mucin, and expansive changes in the affected paranasal sinuses. The diagnosis is based on the diagnostic criteria which were established by John P. Bent, and Frederich A. Kuhn, which are met by 5 to 10% of all cases of chronic rhinosinusites. AFRS is more common in men and presents at a mean age range of 21–33 years. AFRS is a non-invasive form of fungal rhinosinusitis and usually affects individuals with atopy and type I hypersensitivity to fungi. Up to 24% of patients also have bronchial asthma. The mucin has a thick, sticky consistency, which is often described as “peanut butter-like”. Affected sinuses frequently undergo expansive changes that lead to erosion of bony structures. Patients with AFRS are unable to effectively clear fungal spores from the environment. This leads to the epithelial barrier dysfunction and the release of cytokines such as Interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin. This triggers a type 2 immune response and initiates an inflammatory cascade that leads to eosinophilia, nasal polyposis, and the formation of eosinophilic mucin. Surgical intervention is the primary and most essential step in the treatment of AFRS. The goals of surgery include removal of eosinophilic mucin, which contains fungi that provoke and sustain sinus inflammation, excision of nasal polyps, and wide opening of the sinus cavities to facilitate postoperative sinus irrigation and local therapy. Biological medications represent a promising direction for the treatment of chronic rhinosinusitis, especially in patients with comorbid patology such as asthma. The high risk of recurrence highlights the need for further research into new treatment methods and the development of standardized care protocols for future patient management.
- Open Access
- 29 September 2025
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 157 (3) , 82-88
The Impact of Transferred COVID-19 on Sinonasal Symptoms in Patients with Chronic Polyposis Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease
Chronic rhinosinusitis (CRS) is a prevalent disease affecting 5-15% of the population, characterized by prolonged inflammation of the mucosa of the paranasal sinuses. Chronic rhinosinusitis with nasal polyps (CRSwNP) accounts for approximately 18-20% of all CRS cases and has a more severe clinical course compared to CRS without nasal polyps (CRSsNP). A particular group of patients includes those with CRSwNP associated with aspirin-exacerbated respiratory disease (AERD), which comprises asthma, rhinosinusitis with polyps, and intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). This study aimed to evaluate the impact of a past COVID-19 infection on sinonasal symptoms and quality of life in patients with chronic polypous rhinosinusitis and aspirin triad based on the analysis of SNOT-22 questionnaire scores and endoscopic assessment results using the Lund-Kennedy scale. The study was conducted among outpatients at the clinic of the State Institution " O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Sciences of Ukraine." Sixty patients aged 18 to 75 years with a diagnosis of chronic polypous rhinosinusitis with NSAID intolerance were selected and divided into two groups: Group 1 (17 patients) who did not have COVID-19 and Group 2 (43 patients) who had a history of COVID-19. Group 2 was further divided into two subgroups: Subgroup 2A (18 patients, who reported no impact of COVID-19 on the course of CRS) and Subgroup 2B (25 patients, who reported a subjective worsening of CRS after COVID-19). A survey was conducted using the SNOT-22 questionnaire, and endoscopic examination of the nasal cavity was performed with assessment using the Lund-Kennedy scale. The analysis of the SNOT-22 results showed that the mean scores in Group 1 were 41.9 ± 17.94, and in Group 2, they were 43.62 ± 20.12, with no statistically significant differences (p=0.812). The mean scores in Subgroups 2A and 2B were 44.3 ± 19.4 and 43.0 ± 21.2, respectively, also with no statistically significant differences (p=0.874). The endoscopic assessment using the Lund-Kennedy scale did not reveal significant differences between the groups (p=0.588). The study results indicate that a past COVID-19 infection did not have a statistically significant impact on sinonasal symptoms in patients with chronic polypous rhinosinusitis and aspirin triad. COVID-19 did not lead to a significant worsening of the clinical course of the disease, warranting further studies to explore the virus's impact on other aspects of respiratory health in patients with AERD.
- 29 September 2025
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 157 (3) , 82-88
Open AccessThe Impact of Transferred COVID-19 on Sinonasal Symptoms in Patients with Chronic Polyposis Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease
Chronic rhinosinusitis (CRS) is a prevalent disease affecting 5-15% of the population, characterized by prolonged inflammation of the mucosa of the paranasal sinuses. Chronic rhinosinusitis with nasal polyps (CRSwNP) accounts for approximately 18-20% of all CRS cases and has a more severe clinical course compared to CRS without nasal polyps (CRSsNP). A particular group of patients includes those with CRSwNP associated with aspirin-exacerbated respiratory disease (AERD), which comprises asthma, rhinosinusitis with polyps, and intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). This study aimed to evaluate the impact of a past COVID-19 infection on sinonasal symptoms and quality of life in patients with chronic polypous rhinosinusitis and aspirin triad based on the analysis of SNOT-22 questionnaire scores and endoscopic assessment results using the Lund-Kennedy scale. The study was conducted among outpatients at the clinic of the State Institution " O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Sciences of Ukraine." Sixty patients aged 18 to 75 years with a diagnosis of chronic polypous rhinosinusitis with NSAID intolerance were selected and divided into two groups: Group 1 (17 patients) who did not have COVID-19 and Group 2 (43 patients) who had a history of COVID-19. Group 2 was further divided into two subgroups: Subgroup 2A (18 patients, who reported no impact of COVID-19 on the course of CRS) and Subgroup 2B (25 patients, who reported a subjective worsening of CRS after COVID-19). A survey was conducted using the SNOT-22 questionnaire, and endoscopic examination of the nasal cavity was performed with assessment using the Lund-Kennedy scale. The analysis of the SNOT-22 results showed that the mean scores in Group 1 were 41.9 ± 17.94, and in Group 2, they were 43.62 ± 20.12, with no statistically significant differences (p=0.812). The mean scores in Subgroups 2A and 2B were 44.3 ± 19.4 and 43.0 ± 21.2, respectively, also with no statistically significant differences (p=0.874). The endoscopic assessment using the Lund-Kennedy scale did not reveal significant differences between the groups (p=0.588). The study results indicate that a past COVID-19 infection did not have a statistically significant impact on sinonasal symptoms in patients with chronic polypous rhinosinusitis and aspirin triad. COVID-19 did not lead to a significant worsening of the clinical course of the disease, warranting further studies to explore the virus's impact on other aspects of respiratory health in patients with AERD.
- Open Access
- 20 June 2025
- Published by National Scientific Center of Phthisiology, Pulmonology, and Allergology named after F. G. Yanovsky NAMS of Ukraine in Asthma and allergy
- Vol. 24 (2)
Оцінка ефективності та безпеки застосування назального спрею з вмістом n-ацетилцистеїну та гіпертонічного розчину натрію хлориду при хронічному риносинуситі
Резюме. Мета роботи: оцінити ефективність та переносимість назального гіпертонічного сольового розчину з N-ацетилцистеїном в лікуванні пацієнтів з хронічним риносинуситом. Матеріали та методи. Дослідження виконане відповідно до принципів Гельсинської декларації 1975 р. та її перегляду 2000 р. Протокол дослідження ухвалений локальним Комітетом з біоетики та деонтології. Автори заявляють провідсутність конфлікту інтересів. В дослідженні приймали участь 30 хворих з частково контрольованим або неконтрольованим ХРС без наявності назальних поліпів. Пацієнти отримували спрей назальний «ФЛУ-АЦИЛ рино» по три вприскування в кожну ніздрю три рази на день у вигляді монотерапії. Ефективність лікування оцінювали на підставі аналізу суб’єктивних та об’єктивних ознак ХРС, впливу ХРС на якість життя пацієнтів за шкалою ВАШ та риноцитограм пацієнтів до та після лікування. Результати та їх обговорення. У дослідженні продемонстровано регрес об’єктивних і суб’єктивних клінічних проявів ХРС. Поступове зменшення відчуття закладеності носа та об’єктивна ознака «набряк слизової оболонки носа» корелювали під час дослідження. Оцінка в балах симптому «ринорея/постназальне затікання» була достовірно нижчою вже на 5-ту добу, що підтверджувалось на 10-ий день. Такий результат лікування можна пояснити муколітичними властивостями ацетілцистеїну, вміст якого у досліджуваному спреї становить 6 %. Середня оцінка оцінки якості життя в балах ВАШ на десяту добу була достовірно вищою у порівнянні з вихідними даними. Після лікування спостерігався певний зсув риноцитологічної картини, зокрема співвідношення війчастих і келихоподібних клітин, у бік характеристик, притаманних нормальній слизовій оболонці носа. Наприкінці лікування мікрофлора (бактерії, грибкові спори та гіфи) мала нижчу чисельність, ніж базова. На 10-й день спостереження бактеріальні біоплівки були відсутні у двох з 6 пацієнтів, у яких вони були виявлені до лікування. Зареєстровані в КД очікувані випадки побічної дії та позитивна характеристика пацієнтами переносимості досліджуваного засобу свідчить про сприятливий профіль безпеки назального спрею «ФЛУ-АЦИЛ рино». Висновки. Застосування назального спрею «ФЛУ-АЦИЛ рино» сприяє зменшенню вираженості суб’єктивних та об’єктивних ознак ХРС та покращенню якості життя пацієнтів з ХРС. Зменшення ознак запалення слизової оболонки носа хворих на ХРС підтверджено даними напівкількісної характеристики назальних цитограм отриманих до та після лікування. Переносимість застосування назального спрею «ФЛУ-АЦИЛ рино» хворими на ХРС відповідає сприятливому профілю безпеки. Отже, застосування назального спрею «ФЛУ-АЦИЛ рино» в комплексній терапії хворих на ХРС можна вважати раціональним вибором. Отримані обнадійливі клінічні та риноцитологічні результати застосування назального спрею з вмістом ацетілцистеїну мають бути доведені у подальших дослідженнях.
- 20 June 2025
- Published by National Scientific Center of Phthisiology, Pulmonology, and Allergology named after F. G. Yanovsky NAMS of Ukraine in Asthma and allergy
- Vol. 24 (2)
Open AccessОцінка ефективності та безпеки застосування назального спрею з вмістом n-ацетилцистеїну та гіпертонічного розчину натрію хлориду при хронічному риносинуситі
Резюме. Мета роботи: оцінити ефективність та переносимість назального гіпертонічного сольового розчину з N-ацетилцистеїном в лікуванні пацієнтів з хронічним риносинуситом. Матеріали та методи. Дослідження виконане відповідно до принципів Гельсинської декларації 1975 р. та її перегляду 2000 р. Протокол дослідження ухвалений локальним Комітетом з біоетики та деонтології. Автори заявляють провідсутність конфлікту інтересів. В дослідженні приймали участь 30 хворих з частково контрольованим або неконтрольованим ХРС без наявності назальних поліпів. Пацієнти отримували спрей назальний «ФЛУ-АЦИЛ рино» по три вприскування в кожну ніздрю три рази на день у вигляді монотерапії. Ефективність лікування оцінювали на підставі аналізу суб’єктивних та об’єктивних ознак ХРС, впливу ХРС на якість життя пацієнтів за шкалою ВАШ та риноцитограм пацієнтів до та після лікування. Результати та їх обговорення. У дослідженні продемонстровано регрес об’єктивних і суб’єктивних клінічних проявів ХРС. Поступове зменшення відчуття закладеності носа та об’єктивна ознака «набряк слизової оболонки носа» корелювали під час дослідження. Оцінка в балах симптому «ринорея/постназальне затікання» була достовірно нижчою вже на 5-ту добу, що підтверджувалось на 10-ий день. Такий результат лікування можна пояснити муколітичними властивостями ацетілцистеїну, вміст якого у досліджуваному спреї становить 6 %. Середня оцінка оцінки якості життя в балах ВАШ на десяту добу була достовірно вищою у порівнянні з вихідними даними. Після лікування спостерігався певний зсув риноцитологічної картини, зокрема співвідношення війчастих і келихоподібних клітин, у бік характеристик, притаманних нормальній слизовій оболонці носа. Наприкінці лікування мікрофлора (бактерії, грибкові спори та гіфи) мала нижчу чисельність, ніж базова. На 10-й день спостереження бактеріальні біоплівки були відсутні у двох з 6 пацієнтів, у яких вони були виявлені до лікування. Зареєстровані в КД очікувані випадки побічної дії та позитивна характеристика пацієнтами переносимості досліджуваного засобу свідчить про сприятливий профіль безпеки назального спрею «ФЛУ-АЦИЛ рино». Висновки. Застосування назального спрею «ФЛУ-АЦИЛ рино» сприяє зменшенню вираженості суб’єктивних та об’єктивних ознак ХРС та покращенню якості життя пацієнтів з ХРС. Зменшення ознак запалення слизової оболонки носа хворих на ХРС підтверджено даними напівкількісної характеристики назальних цитограм отриманих до та після лікування. Переносимість застосування назального спрею «ФЛУ-АЦИЛ рино» хворими на ХРС відповідає сприятливому профілю безпеки. Отже, застосування назального спрею «ФЛУ-АЦИЛ рино» в комплексній терапії хворих на ХРС можна вважати раціональним вибором. Отримані обнадійливі клінічні та риноцитологічні результати застосування назального спрею з вмістом ацетілцистеїну мають бути доведені у подальших дослідженнях.
- Open Access
- 1 January 2025
- Published by Publishing House Helvetica (Publications)
- No. 5,p. 20-25
EVALUATION OF RISK FACTORS FOR INTRAOPERATIVE BLEEDING IN ENDOSCOPIC SURGERY IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND ASPIRIN-EXACERBATED RESPIRATORY DISEASE
Background. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory disease of the paranasal sinuses that significantly impacts the quality of life. Functional endoscopic sinus surgery is the standard surgical method; however, intraoperative bleeding is a clinically significant issue, especially in patients with aspirin-exacerbated respiratory disease (AERD). Objective. To assess factors associated with increased intraoperative bleeding in patients with CRSwNP and AERD and compare the extent of intraoperative bleeding between AERD and non-AERD groups. Methods. A retrospective analysis was conducted on 40 patients who underwent endoscopic endonasal pansinusotomy (EEP): 27 with AERD and 13 without AERD. Assessed parameters included intraoperative blood loss (mL), surgical field visualization (Boezaart scale), and disease severity (modified Lund–Mackay scale). Statistical analysis involved Student's t-test and Pearson's correlation coefficient (p < 0.05). Results. Patients with AERD had significantly higher intraoperative blood loss (161.9 ± 39.5 mL vs. 108.5 ± 45.0 mL, p = 0.001) and poorer surgical field visibility (Boezaart score: 3.26 ± 0.7 vs. 2.54 ± 0.7, p = 0.009) compared to non-AERD patients. The modified Lund–Mackay score was also higher in AERD patients (36.07 ± 10.5 vs. 27.69 ± 9.9, p = 0.021), indicating an association with increased intraoperative bleeding. Conclusion. Patients with AERD have increased intraoperative bleeding and reduced surgical field visibility. The modified Lund–Mackay score may help predict bleeding risk, highlighting the need for individualized preoperative strategies to minimize surgical complications. У статті представлено результати дослідження факторів, які впливають на інтраопераційну кровотечу під час ендоскопічної ендоназальної хірургії у пацієнтів із хронічним поліпозним риносинуситом (ХРСзНП), асоційованим з аспірин-екзацербованим респіраторним захворюванням (AERD). Вивчено дані 40 пацієнтів, які становили дві групи: з AERD (n = 27) та без AERD (n = 13). Встановлено, що пацієнти з AERD мали значно вищий рівень периопераційної крововтрати (161,9 ± 39,5 мл проти 108,5 ± 45,0 мл, р = 0,001), а також гіршу візуалізацію операційного поля за шкалою Боезарта (3,26 ± 0,7 проти 2,54 ± 0,7, р = 0,009). Виявлено також більшу поширеність поліпозного процесу у пацієнтів з AERD за модифікованою шкалою Lund–Mackay (36,07 ± 10,5 проти 27,69 ± 9,9, р = 0,021), що дає можливість використовувати цей показник як прогностичний маркер ризику інтраопераційної крововтрати. Результати дослідження можуть бути використані для оптимізації передопераційного ведення пацієнтів з AERD з метою профілактики ускладнень під час хірургічного втручання.
- 1 January 2025
- Published by Publishing House Helvetica (Publications)
- No. 5,p. 20-25
Open AccessEVALUATION OF RISK FACTORS FOR INTRAOPERATIVE BLEEDING IN ENDOSCOPIC SURGERY IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND ASPIRIN-EXACERBATED RESPIRATORY DISEASE
Background. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory disease of the paranasal sinuses that significantly impacts the quality of life. Functional endoscopic sinus surgery is the standard surgical method; however, intraoperative bleeding is a clinically significant issue, especially in patients with aspirin-exacerbated respiratory disease (AERD). Objective. To assess factors associated with increased intraoperative bleeding in patients with CRSwNP and AERD and compare the extent of intraoperative bleeding between AERD and non-AERD groups. Methods. A retrospective analysis was conducted on 40 patients who underwent endoscopic endonasal pansinusotomy (EEP): 27 with AERD and 13 without AERD. Assessed parameters included intraoperative blood loss (mL), surgical field visualization (Boezaart scale), and disease severity (modified Lund–Mackay scale). Statistical analysis involved Student's t-test and Pearson's correlation coefficient (p < 0.05). Results. Patients with AERD had significantly higher intraoperative blood loss (161.9 ± 39.5 mL vs. 108.5 ± 45.0 mL, p = 0.001) and poorer surgical field visibility (Boezaart score: 3.26 ± 0.7 vs. 2.54 ± 0.7, p = 0.009) compared to non-AERD patients. The modified Lund–Mackay score was also higher in AERD patients (36.07 ± 10.5 vs. 27.69 ± 9.9, p = 0.021), indicating an association with increased intraoperative bleeding. Conclusion. Patients with AERD have increased intraoperative bleeding and reduced surgical field visibility. The modified Lund–Mackay score may help predict bleeding risk, highlighting the need for individualized preoperative strategies to minimize surgical complications. У статті представлено результати дослідження факторів, які впливають на інтраопераційну кровотечу під час ендоскопічної ендоназальної хірургії у пацієнтів із хронічним поліпозним риносинуситом (ХРСзНП), асоційованим з аспірин-екзацербованим респіраторним захворюванням (AERD). Вивчено дані 40 пацієнтів, які становили дві групи: з AERD (n = 27) та без AERD (n = 13). Встановлено, що пацієнти з AERD мали значно вищий рівень периопераційної крововтрати (161,9 ± 39,5 мл проти 108,5 ± 45,0 мл, р = 0,001), а також гіршу візуалізацію операційного поля за шкалою Боезарта (3,26 ± 0,7 проти 2,54 ± 0,7, р = 0,009). Виявлено також більшу поширеність поліпозного процесу у пацієнтів з AERD за модифікованою шкалою Lund–Mackay (36,07 ± 10,5 проти 27,69 ± 9,9, р = 0,021), що дає можливість використовувати цей показник як прогностичний маркер ризику інтраопераційної крововтрати. Результати дослідження можуть бути використані для оптимізації передопераційного ведення пацієнтів з AERD з метою профілактики ускладнень під час хірургічного втручання.
- 1 January 2025
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- Vol. 8 (5) , 2-12
IMPACT OF HYPOTHYROIDISM AND DIABETES ON THE COURSE OF CHRONIC RHINOSINUSITIS IN PATIENTS WITH A HISTORY OF COVID-19
Background: Hormonal imbalance can significantly affect the physiology of the upper respiratory tract. There is also a correlation between respiratory coronavirus infection COVID-19 and other pathologies of the respiratory tract, in particular chronic rhinosinusitis (CRS). There is a need to study the features of the course of chronic rhinosinusitis and its treatment against the background of concomitant endocrine pathology and a history of COVID-19. Objective: This study was aimed to determine the characteristics of the course of chronic rhinosinusitis against the background of concomitant endocrine pathology in patients who have had COVID-19, and the effectiveness of treatment of patients with CRS and concomitant hypothyroidism and diabetes. Materials and methods: All patients in the study were divided into two groups of 40 people. The 1st group included patients with chronic rhinosinusitis and concomitant hypothyroidism and/or diabetes mellitus. The results of the examination and surgical treatment of patients with CRS in the 1st group were compared with those among patients with CRS without concomitant endocrine pathology (group 2). To determine the characteristics of the course of CRS among patients in the study groups, an assessment of the characteristics of the anamnesis and clinical manifestations of CRS, the quality of life of patients using the SNOT-22 questionnaire, a saccharin test to assess the state of mucociliary clearance in the nasal cavity during the initial examination and 3 months after surgical treatment were used. 3 months after treatment, the degree of improvement of the patient's condition was assessed using the CGI-I scale. Results and discussion: Among patients with concomitant endocrine pathology, there was a negative impact of the coronavirus infection on the course of CRS, which was manifested in the subjective worsening of CRS symptoms and slower recovery from exacerbation of CRS after COVID-19 episodes. CRS in patients with concomitant endocrine pathology is characterized by a more severe clinical course, worse quality of life and slower recovery after surgical treatment. It was determined that patients with thyroid dysfunction and diabetes mellitus have a slower recovery of mucociliary clearance after surgery for CRS compared to patients without concomitant endocrine pathology According to the analysis of the SNOT-22 questionnaire, concomitant thyroid hormone imbalance and diabetes contribute to a worse quality of life in patients with CRS, in particular after surgical treatment Conclusions: Thus, one of the conditions for effective treatment of patients with CRS on the background of hypothyroidism and diabetes mellitus is timely detection and adequate compensation of the existing hormonal dysfunction. In the case of an unfavourable clinical course of CRS, slow postoperative recovery and rapid recurrence after surgery, patients should be examined for subclinical endocrine pathology. Keywords: chronic rhinosinusitis, COVID-19, hypothyroidism, diabetes mellitus.
- 1 January 2025
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- Vol. 8 (5) , 2-12
IMPACT OF HYPOTHYROIDISM AND DIABETES ON THE COURSE OF CHRONIC RHINOSINUSITIS IN PATIENTS WITH A HISTORY OF COVID-19
Background: Hormonal imbalance can significantly affect the physiology of the upper respiratory tract. There is also a correlation between respiratory coronavirus infection COVID-19 and other pathologies of the respiratory tract, in particular chronic rhinosinusitis (CRS). There is a need to study the features of the course of chronic rhinosinusitis and its treatment against the background of concomitant endocrine pathology and a history of COVID-19. Objective: This study was aimed to determine the characteristics of the course of chronic rhinosinusitis against the background of concomitant endocrine pathology in patients who have had COVID-19, and the effectiveness of treatment of patients with CRS and concomitant hypothyroidism and diabetes. Materials and methods: All patients in the study were divided into two groups of 40 people. The 1st group included patients with chronic rhinosinusitis and concomitant hypothyroidism and/or diabetes mellitus. The results of the examination and surgical treatment of patients with CRS in the 1st group were compared with those among patients with CRS without concomitant endocrine pathology (group 2). To determine the characteristics of the course of CRS among patients in the study groups, an assessment of the characteristics of the anamnesis and clinical manifestations of CRS, the quality of life of patients using the SNOT-22 questionnaire, a saccharin test to assess the state of mucociliary clearance in the nasal cavity during the initial examination and 3 months after surgical treatment were used. 3 months after treatment, the degree of improvement of the patient's condition was assessed using the CGI-I scale. Results and discussion: Among patients with concomitant endocrine pathology, there was a negative impact of the coronavirus infection on the course of CRS, which was manifested in the subjective worsening of CRS symptoms and slower recovery from exacerbation of CRS after COVID-19 episodes. CRS in patients with concomitant endocrine pathology is characterized by a more severe clinical course, worse quality of life and slower recovery after surgical treatment. It was determined that patients with thyroid dysfunction and diabetes mellitus have a slower recovery of mucociliary clearance after surgery for CRS compared to patients without concomitant endocrine pathology According to the analysis of the SNOT-22 questionnaire, concomitant thyroid hormone imbalance and diabetes contribute to a worse quality of life in patients with CRS, in particular after surgical treatment Conclusions: Thus, one of the conditions for effective treatment of patients with CRS on the background of hypothyroidism and diabetes mellitus is timely detection and adequate compensation of the existing hormonal dysfunction. In the case of an unfavourable clinical course of CRS, slow postoperative recovery and rapid recurrence after surgery, patients should be examined for subclinical endocrine pathology. Keywords: chronic rhinosinusitis, COVID-19, hypothyroidism, diabetes mellitus.
- 1 January 2025
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- Vol. 8 (1-2) , 46-51
EXTRAOSSEOUS AMELOBLASTOMA OF THE MAXILLARY SINUS: A CLINICAL CASE
Relevance: Ameloblastoma is a rare benign epithelial tumour, considered the most aggressive among benign odontogenic tumours, with a recurrence risk of up to 50% within the first 5 years after treatment. Tumours of the upper jaw are more complex due to their proximity to vital anatomical structures, requiring special attention in diagnosis and treatment. Objective: To draw attention to maxillary ameloblastoma as a rare, aggressive, benign tumour through a clinical case example, highlighting treatment methods and recurrence prevention strategies. Materials and Methods: A patient with complaints of unilateral nasal congestion, difficulty in nasal breathing, and headaches for 6 months was examined at the Department of Inflammatory Diseases of the State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Sciences of Ukraine”. Radiological imaging was performed, specifically computed tomography with intravenous contrast enhancement using Tomohexol. Results and Discussion: CT revealed a soft tissue mass with irregular, indistinct contours on the right side, extending from the upper-medial parts of the maxillary sinus into the nasal cavity. Remodelling of the posterior-lateral wall of the right maxillary sinus was observed. A decision was made to perform endoscopic endonasal tumor removal. During surgery, endoscopic partial septoplasty, right-sided endonasal partial antrostomy type II (TEMP-II), ethmoidotomy, and frontotomy were performed. Extraosseous/peripheral ameloblastoma is the rarest variant of ameloblastoma, predominantly affecting individuals aged 40 to 60, with a slight male predominance – fully consistent with our clinical case. Typically, this tumor does not involve bone destruction, although superficial bone erosion may occur, which distinguishes our patient’s case from descriptions in the literature. The treatment of choice is complete tumour resection with 1-2 cm margins within healthy tissue. There is no evidence supporting chemotherapy or radiation therapy. Conclusions. Ameloblastoma remains poorly understood and, despite its rarity, can affect the maxillary sinuses. Radical resection and regular follow-up are key to successful treatment, as this tumour, despite its benign nature, carries a high risk of recurrence. Keywords: Ameloblastoma, maxilla, neoplasm, odontogenic tumour.
- 1 January 2025
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- Vol. 8 (1-2) , 46-51
EXTRAOSSEOUS AMELOBLASTOMA OF THE MAXILLARY SINUS: A CLINICAL CASE
Relevance: Ameloblastoma is a rare benign epithelial tumour, considered the most aggressive among benign odontogenic tumours, with a recurrence risk of up to 50% within the first 5 years after treatment. Tumours of the upper jaw are more complex due to their proximity to vital anatomical structures, requiring special attention in diagnosis and treatment. Objective: To draw attention to maxillary ameloblastoma as a rare, aggressive, benign tumour through a clinical case example, highlighting treatment methods and recurrence prevention strategies. Materials and Methods: A patient with complaints of unilateral nasal congestion, difficulty in nasal breathing, and headaches for 6 months was examined at the Department of Inflammatory Diseases of the State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Sciences of Ukraine”. Radiological imaging was performed, specifically computed tomography with intravenous contrast enhancement using Tomohexol. Results and Discussion: CT revealed a soft tissue mass with irregular, indistinct contours on the right side, extending from the upper-medial parts of the maxillary sinus into the nasal cavity. Remodelling of the posterior-lateral wall of the right maxillary sinus was observed. A decision was made to perform endoscopic endonasal tumor removal. During surgery, endoscopic partial septoplasty, right-sided endonasal partial antrostomy type II (TEMP-II), ethmoidotomy, and frontotomy were performed. Extraosseous/peripheral ameloblastoma is the rarest variant of ameloblastoma, predominantly affecting individuals aged 40 to 60, with a slight male predominance – fully consistent with our clinical case. Typically, this tumor does not involve bone destruction, although superficial bone erosion may occur, which distinguishes our patient’s case from descriptions in the literature. The treatment of choice is complete tumour resection with 1-2 cm margins within healthy tissue. There is no evidence supporting chemotherapy or radiation therapy. Conclusions. Ameloblastoma remains poorly understood and, despite its rarity, can affect the maxillary sinuses. Radical resection and regular follow-up are key to successful treatment, as this tumour, despite its benign nature, carries a high risk of recurrence. Keywords: Ameloblastoma, maxilla, neoplasm, odontogenic tumour.
- 1 January 2025
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- Vol. 8 (1-2) , 2-7
INFLUENCE OF METABOLIC SYNDROME AND COVID-19 INFECTION ON THE COURSE OF CHRONIC RHINOSINUSIS
Purpose of the study: to determine the main diagnostic criteria in patients with chronic rhinosinusitis with metabolic syndrome, the features of the course of chronic rhinosinusitis after COVID-19 before and after treatment in this category of patients, to determine the volume of surgical treatment in patients with chronic rhinosinusitis with metabolic syndrome according to diagnostic criteria, to evaluate the treatment in the long-term period. Materials and methods: 80 patients with chronic rhinosinusitis, most of whom had a history of Covid-19, were divided into groups: of these, 50 patients were included in group I, in whom metabolic syndrome was observed. Patients with chronic rhinosinusitis without metabolic syndrome made up group II of 30 people. Diagnosis of metabolic syndrome was carried out according to the recommendations of the American Heart Association/National Heart, Lung and Blood Institute criteria. All patients in both groups underwent multispiral computed tomography (MSCT) of the paranasal sinuses with subsequent evaluation of CT studies according to the Lund-Mackay scale. All patients also underwent videoendoscopic examination of the nasal cavity and assessment of the condition of the nasal cavity according to the Lund-Kennedy scale. In order to study the assessment of the quality of life of patients, all patients with CRS underwent a survey according to SNOT-22. The survey according to SNOT-22 was performed before surgical treatment and after surgical treatment after 3, 6, 12 months. Results: According to the Lund-Mackay scale, during CT examination of the condition of the nasal cavity and paranasal sinuses, the average value of the index in patients of group I was higher than in patients of group II. The average value of the Lund-Kennedy scale scores before surgical treatment in patients of group I was also higher than in patients of group II. The average number of points according to SNOT-22 at the initial examination in patients of group I was significantly higher than in patients of group II. The number of surgical interventions for CRS in group I was also greater than in patients without metabolic syndrome. Surgical treatment in the group of patients with metabolic syndrome consisted of the use of more extensive endoscopic interventions. In the surgical treatment of patients without metabolic syndrome, endoscopic surgery was performed more sparingly. In the postoperative period, endoscopic observation of the condition of the nasal cavity was carried out. According to the patient survey for SNOT-22, the average score in patients 3, 6 and 12 months after surgical treatment was significantly higher. In group I, most patients had Covid-19 (80%), of which 27 patients had a prolonged period of CRS (54%). In group II of patients without metabolic syndrome, 18 patients with CRS had COVID-19 (60%), 4 patients had a prolonged period of CRS (13.3%). Conclusions: Patients with CRS with metabolic syndrome are older. When assessing the condition of the nasal cavity after surgical treatment for 3, 6 and 12 months, the manifestations of CRS were more pronounced in the group of patients with metabolic syndrome. The quality of life in patients of group I was restored significantly slower. The duration of the disease was longer in patients with CRS with metabolic syndrome. When assessing the rehabilitation period, it was found that a greater number of patients of group I with CRS who had COVID-19 had a significant prolongation of the postoperative period, compared to group II patients with CRS without metabolic syndrome. Keywords: chronic rhinosinusitis (CRS), metabolic syndrome, COVID-19 infection.
- 1 January 2025
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- Vol. 8 (1-2) , 2-7
INFLUENCE OF METABOLIC SYNDROME AND COVID-19 INFECTION ON THE COURSE OF CHRONIC RHINOSINUSIS
Purpose of the study: to determine the main diagnostic criteria in patients with chronic rhinosinusitis with metabolic syndrome, the features of the course of chronic rhinosinusitis after COVID-19 before and after treatment in this category of patients, to determine the volume of surgical treatment in patients with chronic rhinosinusitis with metabolic syndrome according to diagnostic criteria, to evaluate the treatment in the long-term period. Materials and methods: 80 patients with chronic rhinosinusitis, most of whom had a history of Covid-19, were divided into groups: of these, 50 patients were included in group I, in whom metabolic syndrome was observed. Patients with chronic rhinosinusitis without metabolic syndrome made up group II of 30 people. Diagnosis of metabolic syndrome was carried out according to the recommendations of the American Heart Association/National Heart, Lung and Blood Institute criteria. All patients in both groups underwent multispiral computed tomography (MSCT) of the paranasal sinuses with subsequent evaluation of CT studies according to the Lund-Mackay scale. All patients also underwent videoendoscopic examination of the nasal cavity and assessment of the condition of the nasal cavity according to the Lund-Kennedy scale. In order to study the assessment of the quality of life of patients, all patients with CRS underwent a survey according to SNOT-22. The survey according to SNOT-22 was performed before surgical treatment and after surgical treatment after 3, 6, 12 months. Results: According to the Lund-Mackay scale, during CT examination of the condition of the nasal cavity and paranasal sinuses, the average value of the index in patients of group I was higher than in patients of group II. The average value of the Lund-Kennedy scale scores before surgical treatment in patients of group I was also higher than in patients of group II. The average number of points according to SNOT-22 at the initial examination in patients of group I was significantly higher than in patients of group II. The number of surgical interventions for CRS in group I was also greater than in patients without metabolic syndrome. Surgical treatment in the group of patients with metabolic syndrome consisted of the use of more extensive endoscopic interventions. In the surgical treatment of patients without metabolic syndrome, endoscopic surgery was performed more sparingly. In the postoperative period, endoscopic observation of the condition of the nasal cavity was carried out. According to the patient survey for SNOT-22, the average score in patients 3, 6 and 12 months after surgical treatment was significantly higher. In group I, most patients had Covid-19 (80%), of which 27 patients had a prolonged period of CRS (54%). In group II of patients without metabolic syndrome, 18 patients with CRS had COVID-19 (60%), 4 patients had a prolonged period of CRS (13.3%). Conclusions: Patients with CRS with metabolic syndrome are older. When assessing the condition of the nasal cavity after surgical treatment for 3, 6 and 12 months, the manifestations of CRS were more pronounced in the group of patients with metabolic syndrome. The quality of life in patients of group I was restored significantly slower. The duration of the disease was longer in patients with CRS with metabolic syndrome. When assessing the rehabilitation period, it was found that a greater number of patients of group I with CRS who had COVID-19 had a significant prolongation of the postoperative period, compared to group II patients with CRS without metabolic syndrome. Keywords: chronic rhinosinusitis (CRS), metabolic syndrome, COVID-19 infection.